ROIV vs. ONC, BNTX, TEVA, INSM, SMMT, ITCI, GMAB, RDY, QGEN, and VTRS
Should you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.
Roivant Sciences vs. Its Competitors
BeOne Medicines (NASDAQ:ONC) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.
BeOne Medicines presently has a consensus price target of $320.67, indicating a potential upside of 28.11%. Roivant Sciences has a consensus price target of $16.50, indicating a potential upside of 45.25%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Roivant Sciences is more favorable than BeOne Medicines.
In the previous week, BeOne Medicines had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 11 mentions for BeOne Medicines and 7 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.18 beat BeOne Medicines' score of 0.35 indicating that Roivant Sciences is being referred to more favorably in the news media.
BeOne Medicines has a net margin of -9.40% compared to Roivant Sciences' net margin of -225.71%. BeOne Medicines' return on equity of -7.55% beat Roivant Sciences' return on equity.
BeOne Medicines has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.
Roivant Sciences has lower revenue, but higher earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 6.6% of BeOne Medicines shares are owned by insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Roivant Sciences beats BeOne Medicines on 11 of the 17 factors compared between the two stocks.
Get Roivant Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roivant Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ROIV) was last updated on 7/12/2025 by MarketBeat.com Staff
